Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS960914 A
Publication typeGrant
Publication dateJun 7, 1910
Filing dateSep 21, 1909
Priority dateSep 21, 1909
Publication numberUS 960914 A, US 960914A, US-A-960914, US960914 A, US960914A
InventorsArthur Heinemann
Original AssigneeArthur Heinemann
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Pills for the treatment of diabetes mellitus.
US 960914 A
Abstract  available in
Images(2)
Previous page
Next page
Claims  available in
Description  (OCR text may contain errors)

I liolfirawing.

ARTHUR HEINEMANN, OF LONDON, ENGLAND.

PIL LS FOR THE TREATMENT OF DIABETES MELLITUS.

Specification of Letters Patent.

Application filed September 21, 1909. Serial No. 518,840.

Patented June '7, 1910.

To all whom it'may concern: 7

Be it known that I, ARTHUR HEINEMANN, a subject of the Emperor of Germany, residing at Carlton Mansions, Portsdown Road, Maida Vale, London, W., England, have invented new and useful Improvements in Pills for the Treatment of Diabetes Mellitus, of which the following is a specification.

Diabetes mellitus is a chronic disease of metabolism in which the carbohydrates contained in the food and drink taken by the sufferer are converted into glucose and pass into the urine without contributing to the depend upon the blood for their proper functions it necessarily follows that if the blood can not supply the proper nourishment to said parts the latter will become defective and the blood become charged with abnormal or poisonous matter.

To combat a disease it is necessary to remove its cause. This is effected by the introduction into the blood of a particular substance which in the case of diabetes mellitus must be such as will enable the blood to regain its ability to split up and oxidize the glucose.

The blood, like every other organic matter of vegetable or animal origin, contains enzymes which perform the necessary chemical changes. In the case of diabetes mellitus the blood of the sufferer is not of the proper composition and does not contain either the right or suflicient quantity of enzymes to properly oxidize and assimilate the carbohydrates.

According to my invention I substitute for the natural enzymes, which should be present in the blood, vegetable enzymes,- the socalled oxydases and peroxydaseswhich under certain conditions split up and oxidize the glucose, the products of which are then utilized for the nourishment of the body. But as these enzymes only act in a weak acid or neutral solution and still bet ter in an alkaline solution, and the acid condition of the blood of a diabetic patient is such as to destroy the function,-namely the possibility of utilizing sugar-of even the natural blood enzymes it is necessary to diminish or remove the acidity of the blood. For this Ipurpose I mix the vegetable enzymes wit finely pulverized alkaline salts. The vegetable enzymes and alkaline salts are then formed into pills and coated with keratin or the like, so as to prevent the acids present in the stomach from either reducing or totally annulling the effect of the alkaline enzyme mixture. The pill passes unchanged into the duodenum where it is dissolved by the alkaline liquid present in the intestine. It is then absorbed and passes into the blood, the abnormal amount of acid in the latter being neutralized, so that the natural enzymes of the blood as well as the artificially addedenzymes are able to work under physiological conditions and split up and oxidize the sugar compounds, thus enabling the latter to contribute to the nourishment of the body.

Experience has shown that nearly all vegetable enzymes having an oxidizing effect u on the carbohydrates are useful for the a ove named purpose, especially the oxydases and peroxydases of the genera cucurbita, cochlearia and beta. As regards the alkaline salts to be used those readily absorbed in the intestine such, for instance, as the carbonates of lithium, sodium, potassium and magnesium, and the oxid and peroxid of magnesium should .be employed. Since a peroxydase only acts in the presence of peroxld compounds, it is necessary to always use a peroxld, for example dioxid of magnesium with the peroxydases. The enzyme is prepared from the plant in any suitable or well known manner, such as the following. The leaves, roots or other parts of the plant are inacerated, either with-or without the addition of water, and then if required slightly fermented. The liquid so obtained which contains the enzyme in solution is thenfiltered. and the enzyme successively preci itated and purified by alcohol, ether or ot er suitable means. This constituent is like the corresponding constituent found in yeast and is now known by the same name viz. zymase. The precipitated enzyme or the liquid zymase, as the case may be,

is then mixed with the necessary proportion of alkaline salts and formed mto pills, which are then coated with keratin or other substance incapable of being dissolved by the gastric julce present in the stomach. The pills can be provided with a second coating of such nature as to make them palatable.

In the case of the genus beta the invention could be carried out in the following manner: A suitable quantity of common sugar beets, such for example as 10 kilos is thoroughly cleaned, reduced to a pulp and then subjected to a pressure of, say, 300 atmospheres by means of a suitable hydraulic press. The liquid obtained by this operation, about 7 liters, is then poured into a vessel and mixed with 700 c. c. m. of alcohol of 96% purity, so as to precipitate the sugar and mucous substance contained in the mixture. The liquid in said vessel is removed and filtered, and 45 liters of absolute alcohol added to the filtrate. The resultant precipitate is filtered and Washed with a little absolute alcohol and then placed in a closed vessel. The alcohol is then evaporated preferably at a temperature of about 20 to 30 C. by the withdrawal, by any suitable apparatus, of the air contained in said vessel. The dry powder resulting from the last step, which weighs about 20 grams, is then mixed with 20 grams of magnesium peroxid, 20 ams of lithium carbonate, and 4.8 grams 0 magnesium oxid. This mixture will be sufiicient to form 400 pills or tablets of 0.162 gram, or 24,; grains, each.

I WlSh it to be understood that although I have in the fore oin description advisedly used the wor il it is obvious that the mixture of vegeta le enzymes and alkaline salts may be pressed into the form of small tablets.

Having described my invention, what- I claim and desire to secure by Letters Patent is 1. Pills for the treatment of diabetes mellitus containing a compressed mixture of oxydases and an alkaline salt provided with a coating consistin of a substance insoluble by the gastric juices of the stomach, substantially as described.

2. Pills for the treatment of diabetes mellitus containing a compressed mixture of oxydases of the genus beta and an alkaline salt provided with a coating of' keratin, substantially as described.

,In testimony whereof I have signed my name to this specification in the presence of two subscribing witnesses.

ARTHUR HEINEMANN.

Witnesses: ARTHUR F. ENNIS, F. L. BANDS.

Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US6783546Mar 22, 2001Aug 31, 2004Keraplast Technologies, Ltd.Implantable prosthetic or tissue expanding device
US6849092Mar 8, 2001Feb 1, 2005Keraplast Technologies, Ltd.Implantable prosthetic or tissue expanding device
US6914126Apr 10, 2002Jul 5, 2005Keraplast Technologies, Ltd.Methods for producing, films comprising, and methods for using heterogenous crosslinked protein networks
US6989437Apr 26, 2002Jan 24, 2006Keraplast Technologies, Ltd.Methods for producing, films comprising, and methods for using heterogeneous crosslinked protein networks
US7001987Apr 22, 2002Feb 21, 2006Keraplast Technologies, Ltd.Hydrogel with controllable mechanical, chemical, and biological properties and method for making same
US7001988Sep 25, 2002Feb 21, 2006Keraplast Technologies, Ltd.Methods for controlling peptide solubility, chemically modified peptides, and stable solvent systems for producing same
US7501485Jan 28, 2003Mar 10, 2009Keraplast Technologies, Ltd.Bioactive keratin peptides
US8258093Sep 23, 2011Sep 4, 2012Wake Forest University Health SciencesWound healing compositions containing keratin biomaterials
US8273702Apr 17, 2008Sep 25, 2012Wake Forest University Health SciencesWound healing compositions containing keratin biomaterials
US8299013Feb 16, 2007Oct 30, 2012Wake Forest University Health SciencesClotting and healing compositions containing keratin biomaterials
US8324346Feb 26, 2009Dec 4, 2012Keraplast Technologies, Ltd.Bioactive keratin peptides
US8545893Mar 8, 2011Oct 1, 2013Wake Forest University Health SciencesKeratin biomaterials for treatment of ischemia
US8637231Aug 11, 2011Jan 28, 2014Wake Forest University Health SciencesMethod for increasing the volume of a blood substitute with an expander comprising basic alpha keratose
US8920827Oct 16, 2006Dec 30, 2014Wake Forest University Health SciencesKeratin bioceramic compositions
US8968764Jan 18, 2011Mar 3, 2015Wake Forest University Health SciencesNerve regeneration employing keratin biomaterials
US9068162Feb 12, 2010Jun 30, 2015Wake Forest University Health SciencesKeratin biomaterials for cell culture and methods of use
US9149566Feb 15, 2007Oct 6, 2015Wake Forest University Health SciencesCoatings and biomedical implants formed from keratin biomaterials
US9220754May 16, 2013Dec 29, 2015Wake Forest University Health SciencesKeratin compositions for treatment of bone deficiency or injury
US20030119089 *Sep 25, 2002Jun 26, 2003Dyke Mark VanMethods for controlling peptide solubility, chemically modified peptides, and stable solvent systems for producing same
US20030219486 *Apr 10, 2002Nov 27, 2003Van Dyke Mark E.Methods for producing, films comprising, and methods for using heterogenous crosslinked protein networks
US20030224052 *Apr 22, 2002Dec 4, 2003Van Dyke Mark E.Hydrogel with controllable merchanical, chemical, and biological properties and method for making same
US20030228353 *Jan 28, 2003Dec 11, 2003Keraplast Technologies, Ltd.Bioactive keratin peptides
US20040120910 *Sep 29, 2003Jun 24, 2004Dyke Mark VanMethods for producing, films comprising, and methods for using heterogeneous crosslinked protein networks
US20050058686 *Jul 25, 2003Mar 17, 2005Mark Van DykeBioactive coating for medical devices
US20050169963 *Jan 31, 2005Aug 4, 2005Southwest Ressearch InstituteImplantable prosthetic or tissue expanding device
US20070166348 *Oct 16, 2006Jul 19, 2007Van Dyke Mark EKeratin bioceramic compositions
US20080089930 *Nov 27, 2007Apr 17, 2008Keraplast Technologies, Ltd.Keratin-Based Powders and Hydrogel for Pharmaceutical Applications
US20090004242 *Feb 15, 2007Jan 1, 2009Van Dyke Mark ECoatings and Biomedical Implants Formed From Keratin Biomaterials
US20090148488 *Feb 20, 2009Jun 11, 2009Keraplast Technologies, Ltd.Bioactive coating for medical devices
US20110070276 *Feb 26, 2009Mar 24, 2011Keraplast Technologies, Ltd.Bioactive keratin peptides
US20110137329 *Jan 18, 2011Jun 9, 2011Dyke Mark E VanNerve regeneration employing keratin biomaterials
US20110142910 *Feb 16, 2007Jun 16, 2011Van Dyke Mark EClotting and Healing Compositions Containing Keratin Biomaterials
US20110217285 *Mar 8, 2011Sep 8, 2011Van Dyke Mark EKeratin biomaterials for treatment of ischemia
US20110217356 *Mar 7, 2011Sep 8, 2011Van Dyke Mark EControlled delivery system
Classifications
Cooperative ClassificationA61K9/2886